Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
First Claim
Patent Images
1. A method for treating prostatic tissue with an implant delivery system, comprising:
- accessing an interventional site adjacent prostatic tissue with the implant delivery system;
positioning the implant delivery system to deliver at least a portion of a retaining member within prostatic tissue;
delivering a substance capable of reducing blood flow to prostatic tissue, wherein the substance is a drug, biologic, or cell; and
maintaining compression of prostatic tissue with the retaining member after removal of the implant delivery system from the interventional site.
8 Assignments
0 Petitions
Accused Products
Abstract
Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to improve patency or fluid flow through a body lumen or cavity (e.g., to limit constriction of the urethra by an enlarged prostate gland).
-
Citations
28 Claims
-
1. A method for treating prostatic tissue with an implant delivery system, comprising:
-
accessing an interventional site adjacent prostatic tissue with the implant delivery system; positioning the implant delivery system to deliver at least a portion of a retaining member within prostatic tissue; delivering a substance capable of reducing blood flow to prostatic tissue, wherein the substance is a drug, biologic, or cell; and maintaining compression of prostatic tissue with the retaining member after removal of the implant delivery system from the interventional site. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A method for treating prostatic tissue with an implant delivery system, comprising:
-
accessing an interventional site adjacent prostatic tissue with the implant delivery system; positioning the implant delivery system to deliver at least a portion of a retaining member within prostatic tissue; delivering a substance capable of reducing blood flow to prostatic tissue; and maintaining compression of prostatic tissue with the retaining member after removal of the implant delivery system from the interventional site, wherein compression is maintained for at least three months. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
Specification